Abstract
Background BNT162b2 and mRNA-1273 vaccines are highly protective against COVID-19. Concern about waning immunity and reduced effectiveness against SARS-COV-2 variants led to use of a third dose six months after completing the primary series. We used data from the Veterans Health Administration to evaluate the effectiveness of a third dose of BNT162b2 or mRNA-1273 compared to the primary series in preventing post-vaccination COVID-19.
Methods During January 1 - November 25, 2021, third dose recipients were matched (1:1) to demographically similar controls who did not receive a third dose. Eligible participants had completed the primary series at least six months (180 days) before recruitment date and had received at least one SARS-CoV-2 PCR test. Long-term care residents were excluded. Primary outcomes were documented SARS-CoV-2 infection and COVID-19 hospitalization. Effectiveness was estimated as 1-incidence rate ratio.
Findings Following matching, the BNT162b2 group included 74,032 pairs and the mRNA-1273 group included 55,098 pairs. In BNT162b2 and mRNA-1273 groups, median age was 72 (interquartile range [IQR]: 64-75) and 72 (IQR: 66-77) years, 69,426 (93.8%) and 52,241 (94.8%) were male, and 43,039 (58.1%) and 37,218 (67.5%) were non-Hispanic White, respectively. Effectiveness of a third dose of BNT162b2 or mRNA-1273 compared to the primary series was 45.7% (95% confidence interval [CI]: 37.9-52.5%) and 46.6% (95% CI: 36.4-55.3%) for documented SARS-CoV-2 infection and 44.8% (95% CI: 26.6-58.4%) and 50.0% (95% CI: 26.2-66.1%) for COVID-19 hospitalization, respectively.
Interpretation A third dose of BNT162b2 or mRNA-1273 is moderately effective against post-vaccination COVID-19 infection compared to the primary series.
Funding None.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the Stanford University Institutional Review Board (Protocol ID 47191, "Public Health Surveillance in the Department of Veterans Affairs") and written informed consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.
Data Availability
Due to US Department of Veterans Affairs (VA) regulations, the analytic datasets used for this study are not permitted to leave the VA firewall without a Data Use Agreement. This limitation is consistent with other studies based on VA data.
